^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PGR positive

    i
    Entrez ID:
    5241
    Related biomarkers:
    Expression
    Mutation
    Others
    Apply
    Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy (NCT02945579)
    Phase N/A
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/20/2017
    Primary completion :
    01/31/2026
    Completion :
    01/31/2026
    ER • PGR
    |
    HER-2 positive • HER-2 negative • PGR positive
    Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (NCT04243616)
    Phase 2
    Medical College of Wisconsin
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/05/2020
    Primary completion :
    07/14/2025
    Completion :
    08/13/2025
    HER-2 • PD-L1 • PGR • PD-L2
    |
    PD-L1 expression • HER-2 negative • PGR positive
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • pegylated liposomal doxorubicin • Libtayo (cemiplimab-rwlc)
    The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread (NCT03659136)
    Phase 2
    Boehringer Ingelheim
    Completed
    Last update posted :
    02/24/2025
    Initiation :
    11/28/2018
    Primary completion :
    08/30/2021
    Completion :
    05/11/2022
    HER-2 • PGR
    |
    HER-2 negative • PGR positive
    |
    everolimus • exemestane • xentuzumab (BI-836845)
    Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE) (NCT03691493)
    Phase 2
    Emory University
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    02/08/2019
    Primary completion :
    10/13/2022
    Completion :
    10/13/2022
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa) (NCT05306041)
    Phase 2
    German Breast Group
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    01/02/2023
    Primary completion :
    10/01/2026
    Completion :
    01/01/2027
    HER-2 • PIK3CA • PGR
    |
    HER-2 positive • PIK3CA mutation • PGR positive
    |
    Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery (MACS) (NCT04469296)
    Phase N/A
    Institut du Cancer de Montpellier - Val d'Aurelle
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    05/18/2021
    Primary completion :
    04/01/2026
    Completion :
    04/01/2026
    HER-2 • ER • PGR
    |
    HER-2 negative • PGR positive
    WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor (NCT03854903)
    Phase 1
    Georgetown University
    Completed
    Last update posted :
    02/06/2025
    Initiation :
    04/01/2019
    Primary completion :
    11/01/2023
    Completion :
    01/09/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Ibrance (palbociclib) • fulvestrant • Bosulif (bosutinib)
    Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (NCT00310180)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    04/07/2006
    Primary completion :
    03/02/2018
    Completion :
    09/30/2030
    HER-2
    |
    PGR positive
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease (NCT03865992)
    Phase N/A
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    03/04/2019
    Primary completion :
    10/17/2025
    Completion :
    10/17/2025
    ER • PGR
    |
    ER positive • PGR positive
    Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer (NCT02954874)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/18/2017
    Primary completion :
    05/31/2026
    Completion :
    05/31/2026
    HER-2 • PD-L1 • ER • PGR • CD4
    |
    PD-L1 expression • HER-2 positive • ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) (NCT06018337)
    Phase 3
    DualityBio Inc.
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/18/2024
    Primary completion :
    12/01/2025
    Completion :
    05/01/2028
    HER-2 • PGR
    |
    HER-2 positive • HER-2 expression • HER-2 underexpression • PGR positive
    |
    capecitabine • albumin-bound paclitaxel • trastuzumab pamirtecan (BNT323)
    A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DESTINY-Breast08) (NCT04556773)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    12/17/2020
    Primary completion :
    08/16/2023
    Completion :
    12/04/2025
    HER-2 • PGR
    |
    HER-2 expression • HER-2 underexpression • PGR positive
    |
    Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole
    Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer (NCT03939897)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/17/2020
    Primary completion :
    06/22/2023
    Completion :
    07/16/2025
    HER-2 • ER • PIK3CA • PGR • PTEN
    |
    HER-2 amplification • HER-2 negative • PGR positive
    |
    Verzenio (abemaciclib) • fulvestrant • Aliqopa (copanlisib)
    Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) (NCT05879926)
    Phase 3
    NRG Oncology
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    08/31/2023
    Primary completion :
    01/01/2032
    Completion :
    07/01/2034
    HER-2 • PGR
    |
    HER-2 negative • PGR positive
    |
    triptorelin • goserelin acetate
    Combination Study of SV-BR-1-GM With Retifanlimab (BRI-ROL-001) (NCT03328026)
    Phase 1/2
    BriaCell Therapeutics Corporation
    Enrolling by invitation
    Last update posted :
    02/04/2025
    Initiation :
    03/16/2018
    Primary completion :
    11/03/2025
    Completion :
    11/30/2028
    ER • PIK3CA • PGR
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    cyclophosphamide • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • Bria-IMT (SV-BR-1-GM) • Intron A (interferon α-2b) • cyclophosphamide intravenous
    De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (NCT04852887)
    Phase 3
    NRG Oncology
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    06/07/2021
    Primary completion :
    01/01/2026
    Completion :
    07/01/2041
    HER-2 • PGR
    |
    HER-2 negative • PGR positive
    |
    tamoxifen • letrozole • exemestane
    Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer (TBCRC 050) (NCT03368729)
    Phase 1/2
    University of Alabama at Birmingham
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    09/06/2019
    Primary completion :
    11/01/2026
    Completion :
    12/30/2026
    PGR
    |
    PGR positive • EGFR positive
    |
    Herceptin (trastuzumab) • Zejula (niraparib)
    Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients with Hormone Responsive Stage 0-I Breast Cancer (OSU-13282) (NCT02186470)
    Phase N/A
    Ohio State University Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    04/29/2016
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    ER • PGR
    |
    HER-2 negative • PGR positive
    Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR) (NCT05467891)
    Phase 2
    Oana Danciu
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    09/13/2022
    Primary completion :
    08/01/2028
    Completion :
    08/01/2029
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    tamoxifen • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane
    TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (NCT02693535)
    Phase 2
    American Society of Clinical Oncology
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/14/2016
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    BRAF
    |
    ER positive • HER-2 negative • PGR positive
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • Torisel (temsirolimus) • letrozole • Inlyta (axitinib) • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension
    Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle) (NCT04055493)
    Phase 3
    West German Study Group
    Active, not recruiting
    Last update posted :
    01/14/2025
    Initiation :
    07/02/2019
    Primary completion :
    07/31/2027
    Completion :
    07/31/2027
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Kisqali (ribociclib)
    Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002) (NCT03742895)
    Phase 2
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    12/09/2024
    Initiation :
    12/12/2018
    Primary completion :
    06/30/2026
    Completion :
    06/30/2026
    BRCA1 • BRCA2 • HRD • BRCA
    |
    PGR positive • BRCA mutation
    |
    Lynparza (olaparib) • cisplatin
    Olaparib in Metastatic Breast Cancer (TBCRC 048) (NCT03344965)
    Phase 2
    Beth Israel Deaconess Medical Center
    Active, not recruiting
    Last update posted :
    10/11/2024
    Initiation :
    04/01/2018
    Primary completion :
    07/30/2025
    Completion :
    12/30/2025
    PGR • BRCA1 • BRCA2 • BRCA • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • FANCF • FANCM • FANCD2 • FANCE • FANCC
    |
    HR positive • PALB2 mutation • PGR positive • BRCA mutation
    |
    Lynparza (olaparib)
    A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT) (NCT04569747)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    10/01/2024
    Initiation :
    01/11/2021
    Primary completion :
    09/01/2026
    Completion :
    09/01/2030
    HER-2 • PGR
    |
    HER-2 positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive
    |
    Herceptin (trastuzumab) • tamoxifen • Perjeta (pertuzumab) • letrozole • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension
    FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (NCT03944434)
    Phase 2
    Fondazione Sandro Pitigliani
    Active, not recruiting
    Last update posted :
    09/25/2024
    Initiation :
    12/27/2018
    Primary completion :
    12/27/2024
    Completion :
    11/27/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • triptorelin • goserelin acetate • leuprolide acetate for depot suspension
    Olaparib + Sapacitabine in BRCA Mutant Breast Cancer (NCT03641755)
    Phase 1
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    09/19/2024
    Initiation :
    10/01/2018
    Primary completion :
    04/27/2022
    Completion :
    06/22/2025
    BRCA1 • BRCA2 • BRCA
    |
    HER-2 positive • PGR positive
    |
    Lynparza (olaparib) • sapacitabine (CYC682)
    Niraparib + Dostarlimab in BRCA Mutated Breast Cancer (TBCRC 056) (NCT04584255)
    Phase 2
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    09/19/2024
    Initiation :
    12/18/2020
    Primary completion :
    07/17/2025
    Completion :
    07/17/2029
    HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    HER-2 amplification • HER-2 negative • PALB2 mutation • PGR positive
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) (NCT02032823)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    08/23/2024
    Initiation :
    04/22/2014
    Primary completion :
    03/27/2020
    Completion :
    05/28/2029
    HER-2 • PGR • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • PGR positive
    |
    Lynparza (olaparib)
    NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer (NCT03789110)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    08/20/2024
    Initiation :
    03/08/2019
    Primary completion :
    09/30/2021
    Completion :
    12/30/2024
    HER-2 • PGR • TMB
    |
    HR positive • HER-2 amplification • HER-2 negative • ER positive + PGR positive • PGR positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) (NCT05283837)
    Phase 3
    Zydus Lifesciences Limited
    Completed
    Last update posted :
    07/18/2024
    Initiation :
    09/26/2022
    Primary completion :
    09/06/2023
    Completion :
    09/06/2023
    HER-2 • ER • PGR
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive
    |
    docetaxel • Perjeta (pertuzumab)
    Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer (NCT00893061)
    Phase 3
    Centre Oscar Lambret
    Completed
    Last update posted :
    06/14/2024
    Initiation :
    03/16/2009
    Primary completion :
    04/04/2012
    Completion :
    11/26/2014
    ER
    |
    PGR positive
    |
    tamoxifen • letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer (NCT05378464)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    05/31/2022
    Primary completion :
    07/01/2024
    Completion :
    07/01/2026
    HER-2 • PGR • CD4
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive
    |
    Herceptin (trastuzumab) • Trazimera (trastuzumab-qyyp) • pepinemab (VX15)
    DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). (NCT02035813)
    Phase 2
    Prof. Wolfgang Janni
    Completed
    Last update posted :
    06/04/2024
    Initiation :
    01/01/2014
    Primary completion :
    01/10/2024
    Completion :
    01/10/2024
    ER • PGR
    |
    ER positive • HR positive • HR negative • PGR positive
    |
    Kisqali (ribociclib) • Halaven (eribulin mesylate)
    Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial (Ice3 Trial) (NCT02200705)
    Phase N/A
    IceCure Medical Ltd.
    Completed
    Last update posted :
    05/29/2024
    Initiation :
    10/01/2014
    Primary completion :
    03/17/2024
    Completion :
    05/26/2024
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors (NCT03707340)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    05/27/2024
    Initiation :
    09/14/2018
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    PGR
    |
    PGR positive
    |
    tamoxifen
    A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer (NCT06075758)
    Phase N/A
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    03/07/2024
    Primary completion :
    11/30/2024
    Completion :
    11/30/2024
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Kisqali (ribociclib)
    Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (NCT03671330)
    Phase 2
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    08/29/2018
    Primary completion :
    04/25/2022
    Completion :
    04/15/2025
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Kisqali (ribociclib) • letrozole • anastrozole • goserelin acetate
    Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib (NCT04614194)
    Phase 2
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    05/20/2024
    Initiation :
    04/15/2021
    Primary completion :
    04/15/2026
    Completion :
    04/15/2028
    HER-2 • ER • PGR • CD8
    |
    HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive
    |
    Verzenio (abemaciclib) • letrozole
    FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy (NCT02398773)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/04/2016
    Primary completion :
    04/04/2025
    Completion :
    04/04/2025
    ER • PGR
    |
    ER negative • PGR positive • PGR negative
    APBI Proton Feasibility and Phase II Study (NCT01839838)
    Phase N/A
    Abramson Cancer Center at Penn Medicine
    Completed
    Last update posted :
    05/16/2024
    Initiation :
    04/22/2013
    Primary completion :
    12/23/2022
    Completion :
    12/23/2022
    PGR
    |
    PGR positive
    TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer (TIBET) (NCT04489173)
    Phase 2
    Borstkanker Onderzoek Groep
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    09/25/2020
    Primary completion :
    01/08/2024
    Completion :
    12/01/2024
    HER-2 • ER • PGR
    |
    ER positive • HER-2 negative • PGR positive
    |
    Lonsurf (trifluridine/tipiracil)